1
|
Knebel B, Mack S, Lehr S, Barsch A, Schiller M, Haas J, Lange S, Fuchser J, Zurek G, Müller-Wieland D, Kotzka J. Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). Arch Physiol Biochem 2016; 122:266-280. [PMID: 27373781 DOI: 10.1080/13813455.2016.1197277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Offspring of type 2 diabetes (T2D) patients have increased risk to develop diabetes, due to inherited genetic susceptibility that directly interferes with the individual adaption to environmental conditions. We characterise T2D offspring (OSP) to identify metabolic risk markers for early disease prediction. Plasma of metabolically healthy OSP individuals (n = 43) was investigated after an oral lipid tolerance test (oLTT) by an untargeted mass spectrometric approach for holistic metabolome analyses. Two subgroups of OSP probands can be separated by oLTT, although not differing in general clinical parameters. Analyses of the plasma metabolome revealed mainly medium-chain acylcarnitines and very long-chain fatty acids with differential abundance in the subgroups. The study presented indicates that metabolically healthy OSP of T2D patients differ upon metabolic challenging in serum metabolite composition, especially medium-chain acylcarnitines. The difference suggest that postprandial lipid induced glucose intolerance (LGIT) may serve as a further valuable marker for early diabetes prediction.
Collapse
Affiliation(s)
- Birgit Knebel
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Susanne Mack
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | - Stefan Lehr
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Aiko Barsch
- d Bruker Daltonik GmbH , Bremen , Germany , and
| | - Martina Schiller
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| | - Jutta Haas
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | - Simone Lange
- c Institute for Diabetes Research, Department of General Internal Medicine, Asklepios Klinik St. Georg, Medical Faculty of Semmelweis University , Hamburg , Germany , and
| | | | | | - Dirk Müller-Wieland
- e Department of Internal Medicine I , University Hospital Aachen , Aachen , Germany
| | - Jorg Kotzka
- a Leibniz Center for Diabetes Research, Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf , Düsseldorf , Germany
- b German Center for Diabetes Research (DZD), Muenchen-Neuherberg , Germany
| |
Collapse
|